Igenica Biotherapeutics (immune oncology asset)

Igenica Biotherapeutics (immune oncology asset) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

Igenica Biotherapeutics (immune oncology asset) General Information

Description

A portfolio of immune oncology therapy assets. The assets provide immunotherapies targeting immunological control points that reverse resistance to existing immunotherapies for patients suffering from cancer.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Acquirer
Primary Office
  • 863A Mitten Road.
  • Suite 100B2
  • Burlingame, CA 94010
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Igenica Biotherapeutics (immune oncology asset) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Igenica Biotherapeutics (immune oncology asset)‘s full profile, request access.

Request a free trial

Igenica Biotherapeutics (immune oncology asset) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Igenica Biotherapeutics (immune oncology asset)‘s full profile, request access.

Request a free trial